A Study to Evaluate Raptiva in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
NCT00109317
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
686
Enrollment
INDUSTRY
Sponsor class
Conditions
Psoriasis
Interventions
DRUG:
Raptiva (efalizumab)
Sponsor
Genentech, Inc.